Gene · 3594
Papers2,084
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,084
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of aryl hydrocarbon receptor as a barrier to HIV-1 infection and outgrowth in CD4+ T cells. | Cell Rep | 2023 | 37310858 | PubTator, text mining | PubMed |
| Human IL-35 Inhibits the Bioactivity of IL-12 and Its Interaction with IL-12Rβ2. | Immunohorizons | 2023 | 37289499 | PubTator, text mining | PubMed |
Transcriptomic signatures reveal a shift towards an anti-inflammatory gene expression profile but also the induction of type I and type II interferon signaling networks through aryl hydrocarbon receptor activation in murine macrophages. | Front Immunol | 2023 | 37287978 | PubTator, text mining | PubMed |
| The human Stat1 gain-of-function T385M mutation causes expansion of activated T-follicular helper/T-helper 1-like CD4 T cells and sex-biased autoimmunity in specific pathogen-free mice. | Front Immunol | 2023 | 37275873 | PubTator, text mining | PubMed |
| Multi-omics in Crohn's disease: New insights from inside. | Comput Struct Biotechnol J | 2023 | 37273853 | PubTator, text mining | PubMed |
| Editorial: Interactions between pathogens and host immune system in patients with immunodeficiency: estimation from high-throughput sequencing. | Front Cell Infect Microbiol | 2023 | 37260704 | PubTator, text mining | PubMed |
| Comparison of Effectiveness and Safety of Ustekinumab and Adalimumab As Induction or Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis. | Cureus | 2023 | 37255887 | PubTator, text mining | PubMed |
| Construction of VSVΔ51M oncolytic virus expressing human interleukin-12. | Front Mol Biosci | 2023 | 37255540 | PubTator, text mining | PubMed |
| Autoimmune versus Non-autoimmune Cutaneous Features in Monogenic Patients with Inborn Errors of Immunity. | Biology (Basel) | 2023 | 37237458 | PubTator, text mining | PubMed |
| Psoriasis: A Primer for General Physicians. | Cureus | 2023 | 37228538 | PubTator, text mining | PubMed |
| Plasma protein changes reflect colorectal cancer development and associated inflammation. | Front Oncol | 2023 | 37228491 | PubTator, text mining | PubMed |
| Significant elevated CXCL14 and decreased IL-39 levels in patients with tuberculosis. | Open Life Sci | 2023 | 37215496 | PubTator, text mining | PubMed |
| Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes. | Nat Commun | 2023 | 37208328 | PubTator, text mining | PubMed |
| New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa. | Int J Mol Sci | 2023 | 37176138 | PubTator, text mining | PubMed |
| Methylation of Immune Gene Promoters in Oral and Oropharyngeal Cancer. | Int J Mol Sci | 2023 | 37175405 | PubTator, text mining | PubMed |
| The regulatory role of alternative splicing in inflammatory bowel disease. | Front Immunol | 2023 | 37153612 | PubTator, text mining | PubMed |
| Inhibition of DYRK1B suppresses inflammation in allergic contact dermatitis model and Th1/Th17 immune response. | Sci Rep | 2023 | 37120440 | PubTator, text mining | PubMed |
| A Multigene-Panel Study Identifies Single Nucleotide Polymorphisms Associated with Prostate Cancer Risk. | Int J Mol Sci | 2023 | 37108754 | PubTator, text mining | PubMed |
| mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity. | Cancer Immunol Res | 2023 | 37074216 | PubTator, text mining | PubMed |
| Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab. | Immunohorizons | 2023 | 37071038 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3594/papers?page=10